OS Therapies
OSTX
7 hedge funds and large institutions have $601K invested in OS Therapies in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
390% more capital inflows, than outflows
Capital inflows: $648K | Capital outflows: $132K
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
17% more funds holding
Funds holding: 6 → 7 (+1)
1.11% more ownership
Funds ownership: 0.69% → 1.79% (+1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
CM Management
Gulf Breeze,
Florida
|
+$446K |
| 2 |
Ingalls & Snyder
New York
|
+$86K |
| 3 |
BlackRock
New York
|
+$80.6K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
+$35.2K |
| 5 |
BP
BFC Planning
Cedar Rapids,
Iowa
|
+$277 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$128K |
| 2 |
Morgan Stanley
New York
|
-$4.4K |
OSTX Hedge Fund Activity: Q1 2025 in Review
7 of the 7,493 institutional investors tracked by Wall St. Rank reported a position in OS Therapies (OSTX) for Q1 2025, worth a combined $601K — down 3.7% from $624K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new OSTX positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was CM Management, adding an estimated $446K. The largest seller was Millennium Management, exiting entirely with an estimated $128K sold.
- 7 institutional investors held OS Therapies (OSTX) as of Q1 2025, up from 6 in Q4 2024.
- Funds reported $601K of OS Therapies stock for Q1 2025, down 3.7% quarter-over-quarter.
- 2 funds opened new OS Therapies positions in Q1 2025 and 1 closed out, a net change of +1 holder.
- The largest OS Therapies buyer in Q1 2025 was CM Management, an estimated $446K added.
- The largest OS Therapies seller in Q1 2025 was Millennium Management, an estimated $128K sold.
Based on aggregated 13F filings for Q1 2025.